Muscle and nerve diseases leave thousands of people in the UK unable to walk, breathe, or swallow independently, often from childhood. Decades of research have uncovered the genetic and molecular causes of conditions such as Duchenne muscular dystrophy, yet these discoveries have not led to new treatments that help patients. The gap between understanding a disease at the molecular level and delivering a therapy to a person is wide and persistent. This centre aims to close that gap by combining fundamental molecular research with practical steps that speed translation. The researchers will develop better ways to assess disease progression in both animal models and patients, using techniques such as MRI. They will also build more efficient systems for running clinical trials, create a framework for scientists to study patient samples with consent, and train a new generation of researchers who work across the entire pipeline—from lab bench to bedside. If successful, this integrated approach could accelerate the development of treatments for disabling neuromuscular diseases, changing the outlook for patients and families who currently have few options.
View original technical description
A large number of people in the UK have diseases which affect their muscles and the nerves supplying muscles. Many of these disease are genetic and may develop at a young age causing severe disabilty and early death. A well known example is Duchenne muscular dystrophy but there are many other diseses affecting muscle an nerves that cause a lot of disability. There has been much research into these conditions and advances have been made in understanding the molecular and genetic causes. Unfortunatley this has not translated into new treatments that benefit patients. There are a number of reasons why these discoveries have not benefited patients yet. In this research programme we want to continue making important molecular discoveries but we also want to address this problem of translating molecular discoveries into treatment for patients. We will do this by developing better ways of assessing both animal models and patients using new techniques such as MRI. We will organise better systems for doing clnical trials, we will establish better systems to allow scientists to do research on patient samples with their consent and we will establish better ways of training more new researchers in this important area. We believe that this combined approach of having a single centre that encompasess molecular discovery right through to clinical trials in the patient will be a big advance for helping patients with these disabling diseases.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know